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Abstract
Background: The dominant pattern of failure for squamous cell carcinoma of head and neck remains loco-regional, although
distant metastases are now being increasingly documented. Radical radiotherapy with concurrent chemotherapy is
contemporary standard of care in the non-surgical management of these loco-regionally advanced cancers, based on large
randomized controlled trials utilizing high-dose cisplatin (80–100 mg/m2) cycled every three-weekly during definitive
radiotherapy. Although efficacious, this is associated with high acute morbidity necessitating intensive supportive care with
attendant resource implications. The aim of this retrospective study was to assess the efficacy and acute toxicity of an alternative
schedule i.e. concurrent weekly cisplatin-based radical radiotherapy and it's potential to be an optimal regimen in advanced head
and neck cancers.
Methods: Outcome data of patients with Stage III & IV head and neck squamous cell carcinoma, excluding nasopharynx, planned
for radical radiotherapy (66–70 Gy) with concurrent weekly cisplatin (30 mg/m2) treated in a single unit between 1996–2004
was extracted.
Results: The dataset consisted of 264 patients with a median age of 54 years. The median radiotherapy dose was 70 Gy (range
7.2–72 Gy) and median number of chemotherapy cycles was 6 (range 1–7). Two-thirds (65%) of patients received ≥85% of
planned cisplatin dose. With a mean follow-up of 19 months, the 5-year local control; loco-regional control; and disease free
survival was 57%; 46%; and 43% respectively. Acute grade 3 or worse mucositis and dermatitis was seen in 77 (29%) and 92
(35%) patients respectively, essentially in patients receiving doses ≥66 Gy and 6 or more cycles of chemotherapy. Other
toxicities (hematologic, nausea and vomiting) were mild and self-limiting. Overall, the acute toxicity of this concurrent weekly
chemo-radiation regimen though mildly increased did not mandate intensive supportive care. Stage grouping, primary site, and
intensity of treatment were significant predictors of loco-regional control and disease free survival.
Conclusion: Radical radiotherapy with concurrent weekly cisplatin has moderate efficacy and acceptable acute toxicity with
potential to be an optimal regimen in loco-regionally advanced squamous cell carcinoma of the head and neck, particularly in
limited-resource settings. Stage grouping, primary site, and treatment intensity are important determinants of outcome.
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Background
Squamous Cell Carcinoma of the Head and Neck
(SCCHN) affects 550,000 new patients worldwide annu-
ally [1]. Traditionally surgery and radiotherapy (RT) either
alone for early stage disease or in combination for loco-
regionally advanced disease were considered to have cur-
ative potential [2,3]. Although the dominant presentation
as well as pattern of failure for patients with SCCHN
remains loco-regional, an increasing number of patients
are being diagnosed with distant metastases [4]. The two
most commonly employed strategies of improving out-
come in SCCHN i.e. chemo-radiotherapy (CRT) and
altered fractionation are attempts at treatment intensifica-
tion. Ultimate treatment intensity is limited by patient-
related, disease-specific, and environmental factors.
Although intensification of treatment improves loco-
regional control and consequently survival, it is associated
with high acute morbidity necessitating intensive support-
ive care with resource implications. Recent advances in
translational and clinical research have led to a paradigm
shift wherein radical radiotherapy with concurrent chem-
otherapy (3-weekly high-dose cisplatin) is now consid-
ered the contemporary standard of care in the non-
surgical management of loco-regionally advanced
SCCHN [5-7]. Despite compelling evidence regarding the
benefit of adding chemotherapy, there exists considerable
difficulty in choosing the optimal CRT schedule due to
heterogeneity of study designs and different ways of com-
bining chemotherapy with RT [8].
This retrospective review attempts to analyze a large
cohort of patients with loco-regionally advanced SCCHN
treated uniformly with weekly cisplatin-based concurrent
chemo-radiotherapy. Local control, loco-regional control,
and disease-free-survival (DFS) were considered as meas-
ures of efficacy. Overall survival was not considered as an
end-point, due to high non-cancer-related mortality sec-
ondary to the effects of ageing and prolonged tobacco and
alcohol abuse, existent in this population.
Aims and objectives
The primary aim of this study was to assess the efficacy
and acute toxicity of radical radiotherapy with concurrent
weekly cisplatin and help define an optimal CRT schedule
with tolerable acute toxicity that could be administered
on an outpatient basis to a large majority of patients with
SCCHN without necessitating intensive supportive care in
limited-resource settings. A secondary aim was to identify
prognostic and therapeutic factors affecting outcome
(local control, loco-regional control, and DFS) in patients
with loco-regionally advanced SCCHN undergoing
weekly cisplatin-based definitive concurrent CRT.
Materials and methods
The medical records of all patients with SCCHN treated
with radical RT in a single unit at the institute between
1996 and 2000 were reviewed retrospectively. A prospec-
tive SCCHN database maintained in the department was
searched electronically from 2000 to 2004 to identify eli-
gible patients. Newly diagnosed patients with loco-
regionally advanced American Joint Committee on Can-
cer (AJCC) Stage III & IV SCCHN excluding nasopharyn-
geal cancers who were planned for definitive concurrent
CRT based on a detailed assessment in a multi-discipli-
nary head and neck oncology joint clinic were included.
Patients treated with neoadjuvant, adjuvant, or non-cispl-
atin based chemotherapy were excluded. Patients treated
with conformal techniques were also considered ineligi-
ble due to potential confounding factors. A total of 264
patients were considered suitable and form the dataset for
this analysis.
Radiotherapy
Conventional RT was planned for all patients after appro-
priate immobilization using either a customized plaster of
Paris cast or a thermoplastic mask. All patients were irra-
diated with megavoltage beams either on a telecobalt or a
Linear Accelerator, with conventional fractionation (200
cGy per fraction, one fraction per day, 5 days per week)
with shrinking field technique. The gross tumor volume
was treated to a dose of 66–70 Gy in 33–35 fractions over
6.5–7 weeks. Areas of potential microscopic disease were
treated till 50–60 Gy in 25–30 fractions over 5–6 weeks.
Most patients were treated with bilateral opposing portals
to the face and neck as per the institutional policy. Three-
field technique (bilateral opposing for primary and upper
neck matched onto a low anterior neck field) was used
sparingly at the discretion of the treating oncologist. The
radiation portals were dictated by primary site and disease
stage. Beam modifiers and posterior neck boosts with
appropriate electron energy were used as and when indi-
cated. Spinal cord shielding was applied after 46 Gy in 23
fractions.
Chemotherapy
Cisplatin (30 mg/m2) was administered intravenously
concurrently weekly during the course of radiotherapy.
Routine hydration with 500 mL normal saline given 30–
45 minutes before chemotherapy and 1000 mL of normal
saline given over 2 hours immediately after chemotherapy
was used as per institutional guidelines. Standard anti-
emetic prophylaxis consisted of 16 mg of ondansetron
and 16 mg of dexamethasone given as intravenous bolus
as pre-medication 30 minutes prior to chemotherapy.
Anti-emetic prophylaxis was continued with ondansetron
and domperidone or metoclopramide orally 2–3 days
after each cycle of weekly cisplatin chemotherapy. Forced
diuresis with 20% mannitol was at the discretion of theHead & Neck Oncology 2009, 1:17 http://www.headandneckoncology.org/content/1/1/17
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treating oncologist. Standard guidelines for dose reduc-
tion of cisplatin were applied by indirectly calculating the
glomerular filtration rate based on Cockcroft-Gault for-
mula.
The regimen was administered on an outpatient basis. All
patients were monitored closely weekly during the course
of CRT for assessing the toxicity of therapy. Toxicity grad-
ing was done according to the Radiation Therapy Oncol-
ogy Group (RTOG) and Common Toxicity Criteria (CTC)
grading systems for radiation-related and chemotherapy-
related toxicities respectively. The patients were required
to follow-up at 4–6 weeks from completion of therapy to
assess response, toxicity and disease status. Subsequent
follow-up visits were scheduled at 3–6 monthly intervals
for the first 2 years and annually thereafter. At follow-up
patients underwent thorough clinical examination for
detection of loco-regional disease. Patients who dropped
out or did not complete planned course of treatment were
included as events for all the outcome measures. The dis-
ease status of patients who had completed the planned
course of therapy, but not actively following-up was
updated by telephonic contact. Non-responding patients
were considered lost to follow-up and censored for statis-
tical consideration.
Statistical analysis
Local failure was defined as persistence of disease or reap-
pearance of disease at or in close vicinity to the primary
site. Loco-regional failure was defined as persistence of
disease or reappearance of disease either at the primary
site and/or draining regional lymph nodes. Relapse was
defined as recurrence of disease at either the primary,
regional or distant site or the appearance of a second pri-
mary in the upper aero-digestive tract. The local control,
loco-regional control and DFS were calculated using the
method of Kaplan-Meier. All estimates were calculated
from the date of initiation of therapy till the defined event
if any or until last contact or death. The analysis is limited
to first failures only as a measure of efficacy of concurrent
CRT and does not include outcome after attempted sal-
vage for the stated endpoints. The data was compared
using the log-rank test and Cox regression model for uni-
variate and multivariate analysis respectively. All analysis
was done on SPSS version 14.0 (Statistical Package for
Social Sciences, IL, Chicago).
Results
All patients with AJCC Stage III or IV SCCHN (excluding
nasopharynx) planned for weekly cisplatin-based defini-
tive concurrent CRT were included in the dataset. Patients
receiving even one cycle of weekly cisplatin were consid-
ered eligible. Patients with progressive disease or dropouts
after a few fractions of RT without completing the planned
radical course either due to toxicity or socio-personal rea-
sons were also included in the analysis to reduce bias
inherent in retrospective analyses and as a reflection of
ground realities in routine clinical practice.
Clinical characteristics
The socio-demographic and clinico-pathologic character-
istics of all the analyzable 264 patients with loco-region-
ally advanced SCCHN receiving radical RT with
concurrent weekly cisplatin were consistent with previ-
ously published head and neck literature. The median age
of the cohort was 54 years (range 20–79 years). The sex
ratio was 5:1 in favor of males. Most of the patients had a
good performance status with a median Karnofsky Per-
formance Score (KPS) of 80 (range 60–100). Although
medical co-morbidities consistent with the age-pyramid
were prevalent, they were not significant enough in the
large majority (such as active tuberculosis, uncontrolled
hypertension or diabetes mellitus, or nephropathy) pre-
cluding systemic chemotherapy. The mean and median
total dose of radiation for the entire cohort was 66 Gy and
70 Gy respectively (range 7.2–72 Gy). The median Overall
Treatment Time (OTT) was 51 days with a range of 4–72
days. All patients received some concurrent cisplatin with
the median number of weekly chemotherapy cycles being
6 (range 1–7). More than 65% (n = 169) patients received
>85% of the planned dose of chemotherapy i.e. at least 6
cycles or more of concurrent weekly cisplatin (30 mg/m2).
Efficacy analysis
With a mean follow-up of 17 months (range 0–88
months) for all patients and 19 months (range 0–88
months) for survivors, the 5-year local control; loco-
regional control and DFS was 57.4%; 46.2%; and 43.3%
respectively. Seven patients (2.7%) developed distant
metastases and only 1 (0.4%) metachronous second pri-
mary tumor was detected on follow up. The impact of dif-
ferent prognostic factors on local control, loco-regional
control, and DFS was then analyzed (Table 1). The AJCC
stage grouping was highly significant in terms of all the
outcome measures (Figure 1). The 5-year local control,
loco-regional control and DFS was 68.8%, 66.1%, and
66.1% respectively for stage III disease as compared to
50.3%, 34%, and 29.7% for stage IV with highly signifi-
cant p-values (p < 0.001). T-stage impacted significantly
upon local control and showed some trend on loco-
regional control too. N-stage did not affect local control,
but had significant impact upon loco-regional control and
DFS.
The intensity of treatment affected all three outcome
measures significantly. Patients receiving >85% of the
planned dose (6 or more cycles of weekly chemotherapy)
had a significantly superior 5-year local control (64.5% vs
41.8%, p = 0.022); loco-regional control (54.4% vs
26.8%, p = 0.009); and DFS (49.6% vs 25.8%, p = 0.011)Head & Neck Oncology 2009, 1:17 http://www.headandneckoncology.org/content/1/1/17
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as compared to lesser dose intensity (1–5 cycles of chem-
otherapy) (Figure 2). On the basis of total dose of RT
delivered, the patients were categorized into two dose
groups, viz. <70 Gy; and ≥70 Gy. The 5-year local control
in patients receiving <70 Gy was 51.2% as compared to
60.2% in patients receiving ≥70 Gy (p = 0.28). Similarly
patients receiving higher total doses had better 5-year
loco-regional control (50.5% vs 37.4%, p = 0.125) and
DFS (45.6% vs 35.9%, p = 0.142). A separate analysis with
66 Gy as cut-off dose instead of 70 Gy also only showed
some trend towards improved outcome with higher doses
but was not statistically significant (data not shown). The
reasons for choosing 66 and 70 Gy as the cut-off points
was based on mean and median radiotherapy dose in this
study cohort and previously published head and neck
radiotherapy literature where radical doses have been
defined as 66–70 Gy conventional fractionation equiva-
lent. Overall treatment time (OTT) as a measure of treat-
ment intensity was considered only for the 213 patients
receiving at least 66 Gy. For this cohort, OTT was a signif-
icant predictor of outcome, with patients completing
treatment in a shorter time (≤51 days) faring better overall
than patients with longer OTT (>51 days). The 5-year local
control (67.7% vs 51.1%, p = 0.029), loco-regional con-
trol (59.9% vs 39.3%, p = 0.013), and DFS (56.5% vs
35.5%, p = 0.016) was significantly better for patients
completing optimal treatment within the planned time-
frame. The cut-off for OTT was chosen at 51 days as it was
the median of this cohort.
Primary site was also a prognosticator of outcome (Figure
3). Patients with oral primaries fared the worst, with a 5-
Table 1: Univariate analysis for local control, loco-regional control & disease free survival
Prognostic factor Patients 5-yr LC p-value 5-yr LRC p-value 5-yr DFS p-value
Age
> 54 yrs 110 46.8% 0.057 36.2% 0.067 35.0% 0.123
≤ 54 yrs 154 65.1% 53.6% 49.0%
HP Grade
NOS 232 55.2% 0.115 44.2% 0.153 41.8% 0.241
WD 04 33.3% 33.0% 33.3%
MD 05 80.0% 40.0% 40.0%
PD 23 73.7% 64.2% 55.2%
T stage
T1-T2 53 73% 0.004 43.4% 0.079 36.1% 0.078
T3 153 59% 50.7% 49.3%
T4 58 50% 36% 33.8%
N stage
N0 64 66.0% 0.212 66.0% 0.001 66.0% 0.001
N1 61 58.1% 54.1% 54.1%
N2-3 139 51.9% 31.9% 27.0%
Stage Group
III 96 68.8% 0.005 66.1% 0.001 66.1% 0.001
IV 168 50.3% 34.0% 29.7%
Primary site
Oral cavity 18 13.9% 0.001 13.9% 0.012 13.9% 0.026
Oropharynx 118 58.6% 50.7% 47.7%
Hypopharynx 93 59.3% 45.0% 42.9%
Larynx 35 71.9 50.2% 44.4%
RT dose
< 70 Gy 51 51.2% 0.280 37.4% 0.125 35.9% 0.142
≥ 70 Gy 213 60.2% 50.5% 45.6%
CT cycles
1–5 96 41.8% 0.022 26.8% 0.009 25.8% 0.011
≥ 6 168 64.5% 54.4% 49.6%
KPS
< 80 51 46.4% 0.215 33.0% 0.183 30.3% 0.133
≥ 80 213 60.1% 49.3% 82.2%
OTT
≤ 51 days 116 67.7% 0.029 59.9% 0.013 56.5% 0.016
> 51 days 97 51.1% 39.3% 35.5%
LC = local control; LRC = loco-regional control; DFS = disease free survival; NOS = not otherwise specified; WD = well differentiated; MD = 
moderately differentiated; PD = poorly differentiated; RT = radiotherapy; CT = chemotherapy; KPS = Karnofsky Performance Status; OTT = 
overall treatment timeHead & Neck Oncology 2009, 1:17 http://www.headandneckoncology.org/content/1/1/17
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Stage grouping as prognostic factor for local control (a), loco-regional control (b), and disease-free survival (c) in SCCHN  treated with concurrent chemo-radiotherapy Figure 1
Stage grouping as prognostic factor for local control (a), loco-regional control (b), and disease-free survival (c) 
in SCCHN treated with concurrent chemo-radiotherapy.
a
b
cHead & Neck Oncology 2009, 1:17 http://www.headandneckoncology.org/content/1/1/17
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Impact of intensity of chemotherapy on local control (a), loco-regional control (b), and disease-free survival (c) in weekly cispl- atin-based concurrent chemo-radiotherapy for SCCHN Figure 2
Impact of intensity of chemotherapy on local control (a), loco-regional control (b), and disease-free survival (c) 
in weekly cisplatin-based concurrent chemo-radiotherapy for SCCHN.
a
b
cHead & Neck Oncology 2009, 1:17 http://www.headandneckoncology.org/content/1/1/17
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year local control, loco-regional control, and DFS of
13.9% each. In contrast patients with laryngeal and
oropharyngeal cancers had the best 5-year outcomes.
Their 5-year local control, loco-regional control and DFS
was 71.9% & 58.6%; 50.2% & 50.7%; and 44.4% & 47.7%
respectively. Hypopharyngeal primaries fared intermedi-
ately with 5-year outcomes of 59.3%, 45%, and 42.9% for
local control, loco-regional control and disease free sur-
vival respectively. Oral cavity as a primary site has previ-
ously also been demonstrated as a poor prognostic factor,
whereas larynx and oropharynx have done consistently
better. A subset analysis of TNM stage grouping within
each primary site re-inforced the importance of stage as
the most significant determinant of outcome. The 5-year
local control, loco-regional control and DFS were consist-
ently and significantly better in Stage III as compared to
Stage IV disease within each primary site (Table 2).
Younger age as a prognostic factor did show a trend
towards improved local and regional control which did
not reach statistical significance (borderline significant p
values). It is well-accepted that older patients tend to have
worse outcomes with aggressive schedules due to lower
compliance and higher toxicity rates. Patients with good
KPS also tended to do better, although once again it was
not statistically significant. Histological grade and sex
were not found to affect outcome significantly. All factors
that were of significance or of borderline significance on
univariate analysis were considered for multivariate anal-
ysis. Multivariate analysis using Cox proportional hazards
model confirmed the importance of AJCC stage grouping,
total chemotherapy dose, and primary site as significant
and independent prognostic factors (Table 3).
Toxicity analysis
The RTOG acute grade 3 or worse mucositis and dermati-
tis was seen in 77 (29.2%) and 92 (34.8%) patients
respectively, most of the time in patients receiving more
intense treatment i.e. doses ≥66 Gy and 6 or more cycles
of chemotherapy. Mild to moderate nausea and vomiting
occurred in almost all patients despite anti-emetic proph-
ylaxis. CTC grade 3 or worse emesis occurred in 9 (3.4%)
patients, mostly towards the end of chemo-radiotherapy.
Acute hematologic toxicity in the form of leucopenia and
thrombocytopenia was mild and acceptable. The inci-
dence of CTC grade 3 leucopenia was 5.7%. No episodes
of febrile neutropenia were recorded. No patients experi-
enced CTC grade 3 thrombocytopenia. Platelet transfu-
sion or growth factor support due to acute hematologic
toxicity was not needed in any patient. There was minimal
acute kidney dysfunction, with no episodes of grade 3 or
worse renal toxicity because the dose of cisplatin was
titrated based on indirect estimation of glomerular filtra-
tion rate prior to each cycle of weekly chemotherapy. Tox-
icity of treatment leading to interruption or compromise
in the planned dose of radiotherapy was seen in 40 (15%)
patients. Twenty (7.5%) patients had to be hospitalized
for supportive care. Only 5 (2%) patients dropped out of
treatment and did not complete even 50 Gy of RT, mostly
due to social and personal reasons and not due to toxicity.
Overall the regimen was well tolerated with acceptable
acute toxicity. An analysis of late effects of the regimen
was not attempted due to lack of proper documentation
of late toxicity.
Salvage treatment at relapse was individualized and at the
discretion of the treating oncologist. The majority of
patients (42/68) with relapse were offered best supportive
care alone. Salvage surgery was attempted in 22 patients,
6 of whom received adjuvant re-irradiation based on sur-
Table 2: Outcomes within each primary site correlated with AJCC stage
No. of patients 5-yr LC p-value 5-yr LRC p-value 5-yr DFS p-value
Oral cavity
Stage III 2 50% 0.13 50% 0.13 50% 0.13
Stage IV 16 8.1% 8.1% 8.1%
Oropharynx
Stage III 40 68.8% 0.08 68.8% 0.01 68.8% 0.004
Stage IV 78 53.6% 36.4% 29.5%
Hypopharynx
Stage III 42 66.9% 0.16 59.3% 0.01 59.3% 0.009
Stage IV 51 53.2% 34.4% 31.2%
Larynx
Stage III 12 80.2% 0.83 80.2% 0.15 80.2% 0.07
Stage IV 23 67.8% 34.3% 28%
LC = local control; LRC = loco-regional control; DFS = disease-free survivalHead & Neck Oncology 2009, 1:17 http://www.headandneckoncology.org/content/1/1/17
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Correlation of primary site with local control (a), loco-regional control (b), and disease-free survival (c) in loco-regionally  advanced SCCHN treated with concurrent chemo-radiotherapy Figure 3
Correlation of primary site with local control (a), loco-regional control (b), and disease-free survival (c) in loco-
regionally advanced SCCHN treated with concurrent chemo-radiotherapy.
a
b
cHead & Neck Oncology 2009, 1:17 http://www.headandneckoncology.org/content/1/1/17
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gical pathology. Palliative chemotherapy with or without
re-irradiation was considered appropriate for 4 patients.
However since very few patients were effectively salvaged,
this analysis did not attempt to consider the impact of sal-
vage therapy on final outcome restricting itself to first fail-
ures alone, a measure of the efficacy of radical chemo-
radiotherapy as definitive treatment.
Discussion
This study represents one of the largest single-centre expe-
riences of weekly cisplatin concurrently with radiotherapy
in the non-surgical management of loco-regionally
advanced SCCHN. Patients who were offered upfront sur-
gery followed by adjuvant chemo-radiotherapy were not
considered for this study and constitute the dataset of a
separate report. This study confirms the importance of
AJCC stage grouping, intensity of treatment, and primary
site as significant predictors of outcome, consistent with
published head and neck literature.
The most robust evidence recommending platinum-based
concurrent CRT as the standard of care for loco-regionally
advanced SCCHN comes form rigorously conducted ran-
domized controlled trials and meta-analyses [5-7] using
mortality as outcome of interest. The updated meta-anal-
ysis of chemotherapy in head and neck cancer (MACH-
NC) confirmed the findings of the original report of 4%
overall survival benefit with chemotherapy [6,7]. It also
demonstrated a relative 19% improvement in survival
(hazard ratio 0.81; p < 0.001) for concomitant therapy
translating into an 8% absolute benefit in overall survival
with platinum-based regimens in the concurrent setting.
However, little is known about the extent to which con-
current CRT for SCCHN has been adopted in the commu-
nity setting and whether benefits commensurate with
those reported in trial setting are achieved in community
practice [8,9]. Despite robust evidence and consistent
guidelines [10,11], uncertainties exist regarding appropri-
ate CRT regimens because of significant heterogeneity in
published data with respect to patient selection, chemo-
therapy schedules and RT fractionation [8,9]. RT still
remains the primary and definitive component of concur-
rent chemo-radiation. Therefore, it is imperative that con-
current chemotherapy be integrated into the same
radiation regimen that would constitute optimal treat-
ment if radiotherapy was administered as mono-therapy.
A fundamental corollary is that a concurrent CRT regimen
proven superior only to a sub-optimal radiation alone reg-
imen does not constitute optimal therapy [12]. The
increased efficacy of CRT needs to be carefully balanced
against the enhanced acute and perhaps even long-term
toxicity. Enhanced acute toxicity leading to interruption
or modification of radiation delivery may potentially
compromise on the efficacy of treatment. Intensive sup-
portive care with liberal use of feeding tubes, intravenous
hydration and narcotic analgesics may be a challenge even
for seasoned health-care providers [13] with attendant
resource implications.
The putative mechanisms of synergistic interaction of cis-
platin with radiotherapy in SCCHN include radiosensi-
tizer (through inhibition of potentially lethal damage
repair and sublethal damage repair); hypoxic cell sensi-
tizer; cell cycle pertubator; ability to form deoxyribonu-
cleic acid (DNA) adducts; and inhibition of angiogenesis
[14]. Concurrent 3-weekly high-dose cisplatin (100 mg/
m2) is contemporary 'standard of care' for loco-regionally
advanced SCCHN based on level I evidence [5,6]. How-
ever, only 60% of patients in clinical trial setting are able
to receive all the three planned doses of three-weekly cis-
platin due to unacceptably high systemic and mucosal
toxicities [12,15]. The lack of uniform reporting of side
effects and small size of individual studies limits conclu-
sions about the relative tolerability of one regimen over
the other. Schedules that deliver smaller doses at more fre-
quent intervals are also quite effective in improving out-
come. More frequent administration could provide better
radio-sensitization to a larger proportion of the adminis-
tered radiotherapy dose [12]. Marcu and colleagues [16]
studied the scheduling of cisplatin with radiotherapy in a
previously developed tumor growth model of SCCHN by
implementing the kinetics of cisplatin and concluded that
Table 3: Significant factors in multivariate analysis for outcome measures
Prognostic factor p-value Hazard Ratio 95% Confidence Interval
Local Control
Stage grouping (III vs IV) 0.013 1.816 1.134 – 2.908
Primary site (oral vs non-oral) 0.001 0.648 0.497 – 0.845
No of CT cycles (less vs more) 0.038 0.643 0.424 – 0.977
Loco-regional Control
Stage grouping (III vs IV) 0.000 2.406 1.551 – 3.734
No of CT cycles (less vs more) 0.014 0.627 0.432 – 0.909
Disease Free Survival
Stage grouping (III vs IV) 0.000 2.640 1.707 – 4.081
No of CT cycles (less vs more) 0.016 0.642 0.447 – 0.922Head & Neck Oncology 2009, 1:17 http://www.headandneckoncology.org/content/1/1/17
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daily low dose immediately prior to each fraction of radi-
ation could result in best radiosensitization. Smaller indi-
vidual doses of the drug may also result in lesser
chemotherapy induced morbidity without compromising
the efficacy. Although no phase I data for weekly schedul-
ing of cisplatin for SCCHN existed, the dose-intensity of
prevailing regimens was in the range of 25–33 mg/m2 per
week. Similar weekly regimen was being offered to
patients with carcinoma cervix with radical radiotherapy
as an institutional policy. There are now several reports
showing benefit in loco-regional control and/or survival
with alternative cisplatin regimens, i.e. 5 doses of 20 mg/
m2 for 5 consecutive days [17] or 4 doses of 25 mg/m2 for
4 consecutive days [18] during weeks 1, 4, and 7 of radio-
therapy; weekly doses of 40–60 mg for 6–7 weeks [19,20];
and 5–7 mg/m2/day, 5 days a week during a 7 week course
of fractionated radiotherapy [21-23].
The uncertainty regarding the optimal scheduling of cispl-
atin with radiotherapy in SCCHN has sparked considera-
ble interest in comparing various dose-schedules. In the
first such comparative study [24], 51 patients received cis-
platin (100 mg/m2 over 2–3 days) during weeks 1, 4, and
7, while 32 patients received cisplatin (40 mg/m2) weekly
during definitive radiotherapy. Contrary to expectations,
the incidence of severe acute toxicity (skin, hematological,
treatment interruptions, weight loss, and mucositis) was
significantly higher (p = 0.005) in the weekly cisplatin
arm, prompting the authors to suggest chemotherapy
dose reduction and prophylactic feeding tube placements
in the weekly arm. In another indirect comparison, Ho
and colleagues [25], compared the differences in dose
intensity, delays, and toxicity between concurrent 3-
weekly (80–100 mg/m2) and weekly (40 mg/m2) cispla-
tin-based definitive CRT in 51 patients with advanced
SCCHN. More patients received a higher cumulative dose
of at least 240 mg/m2 in the weekly arm as compared to
the 3-weekly arm (p = 0.04). The 3-weekly regimen was
associated with more delays (41% vs 29%) and omissions
of chemotherapy (17.4% vs 5.6%) resulting in lesser
patients achieving cumulative doses beyond 200 mg/m2,
potentially lowering dose-intensity. A prospective non-
randomized study [26] compared 3-weekly cisplatin (100
mg/m2) given to younger patients with good KPS (n = 30)
with weekly cisplatin (40 mg/m2) in patients with older
age or poor KPS (n = 20) along with radical radiotherapy.
The complete response rate (50% vs 40%), overall
response rate (92% vs 90%), and grade III-IV toxicities
(53% vs 40%) were similar in the two cohorts. The only
randomized study comparing daily (6 mg/m2), weekly
(40 mg/m2), and three-weekly (100 mg/m2) schedule of
cisplatin with conventionally fractionated radiotherapy
[27] did not find any significant difference in the efficacy
of the regimens (similar response rates and loco-regional
control), but reported varying degrees of mucosal, renal
and hematologic toxicity. Overall the available data sug-
gests that a cumulative cisplatin dose of 200–250 mg/m2
given three-weekly, weekly, or daily during radiotherapy
yields therapeutic benefit [12,15].
The most popular schedule of concurrent cisplatin for
SCCHN outside the context of clinical trials is not the
three-weekly regimen but a weekly schedule [28] of cispl-
atin in the dose range of 30–40 mg/m2. Most of the bias
against using weekly cisplatin stems from the negative
results of a single inter-group trial [29] which has been
reported only in abstract form. There was no difference in
outcome for 319 evaluable patients randomized to con-
current weekly cisplatin plus conventionally fractionated
radiotherapy versus radical radiotherapy alone. However,
approximately 15% of patients in the trial were nasopha-
ryngeal cancers and the final results have never been pub-
lished in full form. Although additional data from the trial
was made available for the MACH-NC analysis, it is inad-
equate to draw definitive conclusions regarding the effi-
cacy of weekly cisplatin. In a more recent phase III trial
[30], involving 153 stage II-IV oropharyngeal and
nasopharyngeal cancer patients, Sharma et al reported
improved response rates (79.2% vs 69.7%, p < 0.05) and
3-year overall survival (62% vs 42%, p = 0.024) for con-
current weekly cisplatin as compared to radical radiother-
apy alone. This however, was achieved at the cost of
increased grade III-IV toxicities (40% vs 16%, p < 0.05),
more frequent interruptions (28.9% vs 9.3%, p < 0.05),
and hospitalization (40.8% vs 20%, p < 0.05), prompting
the authors to conclude that the enhanced toxicity of con-
current chemoradiation remains an area of concern for
the constrained medical infrastructure of a developing
country economy.
Some of the current generation co-operative group trials
are also using weekly chemotherapy with single agent car-
boplatin with or without taxanes in the concurrent setting
for loco-regionally advanced SCCHN [15], either as defin-
itive treatment or after induction chemotherapy.
Recent evidence supports the use of altered fractionation
for improvement in outcome for SCCHN [31]. Concur-
rent chemotherapy with altered fractionation has the
potential to improve outcomes significantly [18,19] albeit
at the cost of substantially increased acute and late toxicity
[32,33]. Since the toxicity of weekly cisplatin in the given
dose range is substantially lower than the high-dose three-
weekly schedules, combining weekly chemotherapy with
altered fractionation may be more acceptable to the prac-
ticing oncologist.
Conclusion
This study reports on one of the largest single-centre expe-
rience of weekly cisplatin concurrently with radiotherapyHead & Neck Oncology 2009, 1:17 http://www.headandneckoncology.org/content/1/1/17
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with potential to be an optimal therapeutic regimen in the
non-surgical management of loco-regionally advanced
SCCHN. AJCC stage grouping, intensity of treatment, and
primary site were significant and independent predictors
of outcome. The efficacy of this regimen is largely compa-
rable to other contemporary series. Acute toxicity is sub-
stantially lower than previously reported for more
intensive CRT schedules. There is significant scope for fur-
ther optimizing cisplatin-based concurrent chemoradio-
therapy regimens through rigorous pharmacokinetic and
radiobiologic modeling. Larger prospective trials explor-
ing various schedules of cisplatin (dose, route, frequency,
and sequence) are warranted in order to find the most
optimal way of combining the drug with radiation.
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